AstraZeneca recently announced its long-acting monoclonal antibody (mAbs) was recently added to the list of Best Inventions of 2022 by TIME.
EVUSHELD™ is the first and only long-acting mAbs to receive authorization in the U.S. to prevent COVID-19 in immunocompromised people.
"Immunocompromised individuals have lived a very different pandemic experience than most of us," said Joris Silon, U.S. Country President, BioPharmaceutical Business Unit, AstraZeneca, in a press release on November 10, 2022.
Antibody Against SARS-CoV-2 Joined Best Inventions of 2022
Emergency Visits for Child Suicidal Ideation Increased in Illinois in 2019
Increase started in 2019 and continued through pandemic; hospitalizations increased 57 percent between Fall 2019 and Fall 2020
Moderna Booster Shot Prompts Strong Immune Response Against Omicron Subvariants
Moderna reports its updated booster shot is indeed triggering a strong immune response to the omicron variants BA.5 and BA.4
New Health Problems Post-COVID-19 Also Seen in Children, Teens
Common symptoms developing three or more months after COVID-19 infection differ between adults and children/adolescents
America’s Emergency Physicians Warn of Surge in Patients Due to ‘Tripledemic’
A coalition of health and medical groups has called on the White House to hold a summit on ongoing problems facing U.S. emergency departments